Is there a ray of hope for Big Pharma's brands in India? Maybe--but maybe not. Two months after officials pulled Pfizer's ($PFE) patent on the cancer drug Sutent, the Supreme Court says the Patent Office has to reconsider the case.
India has blown another raspberry at Big Pharma. In its third strike against foreign drugmakers, the Indian patent office yanked Pfizer's ($PFE) patent on the kidney cancer drug Sutent. The move was a victory for local drugmakers Cipla and Natco Pharma, which legally protested Sutent's patent protection.
Indian genericsmaker Natco Pharma, having knocked off Bayer's cancer drug Nexavar with a compulsory license, says it is lining up the targets it wants to shoot at next.
Nexavar did deliver "an improvement" in progression-free survival, the companies said, but that was the study's secondary endpoint.
More evidence that drugs and diagnostics will be playing together often: Researchers sequencing genes in colon and lung tumors found mutations that could be targeted with existing drugs. The study
As pharma companies expand their use of DNA sequencing for drug R&D, researchers have uncovered some potential new targets for existing cancer drugs that are likely to spur further use of
Shares of Paris-based AB Science shot up yesterday after the drug developer reported strong efficacy results from a midstage study of its experimental drug for gastrointestinal tumors. The treatment,
FDA's expert advisors gave two thumbs up yesterday, one for Pfizer ( $PFE ) and one for Novartis ( $NVS ). The companies' cancer drugs Sutent and Afinitor won backing from the panel as treatments for a
With cancer drugs, the first approval is only the beginning. An indication for one type of cancer can become two or three if drugmakers play their cards right--and if the treatments themselves prove
When Steve Jobs began another medical leave last week, Apple didn't release any details about its CEO's health. But that hasn't stopped observers from conjecturing. Bloomberg takes a close look at